Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth O Hexner

Showing results (1-10 of 105) with videos related to

Pageof 11
Sort By:
Haematologica|October 12, 2023
The splendor and the tyranny of JAK inhibitionElizabeth O Hexner
Current Opinion in Hematology|October 16, 2007
JAK2 V617F: implications for thrombosis in myeloproliferative diseasesElizabeth O Hexner
American Journal of Hematology|March 24, 2025
Update in GVHD Prophylaxis: Novel Pharmacologic and Graft Manipulation StrategiesElizabeth O Hexner, Zachariah DeFilipp
Expert Opinion on Biological Therapy|December 2, 2005
RNA interference for treating haematological malignanciesElizabeth O Hexner, Alan M Gewirtz
Hematology. American Society of Hematology. Education Program|December 10, 2021
Running interferon interference in treating PV/ET: meeting unmet needsElizabeth A Traxler, Elizabeth O Hexner
Case Reports in Hematology|October 16, 2019
Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic LeukemiaRonak H Mistry, Elizabeth O Hexner, James K Mangan
Therapeutic Advances in Hematology|April 5, 2013
Myelofibrosis 2012: it's complicatedHarper G Hubbeling, Dale M Frank, Elizabeth O Hexner
Blood|March 27, 2010
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2Wei Wang, Sven Schwemmers, Elizabeth O Hexner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2013
Intrinsic resistance to JAK2 inhibition in myelofibrosisAnna Kalota, Grace R Jeschke, Martin Carroll, et al.
Cancer Treatment and Research|September 26, 2009
Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantationDavid L Porter, Elizabeth O Hexner, Sarah Cooley, et al.
Pageof 11

Showing results (1-10 of 105) with videos related to

Sort By:
Pageof 11
Haematologica|October 12, 2023
The splendor and the tyranny of JAK inhibitionElizabeth O Hexner
Current Opinion in Hematology|October 16, 2007
JAK2 V617F: implications for thrombosis in myeloproliferative diseasesElizabeth O Hexner
American Journal of Hematology|March 24, 2025
Update in GVHD Prophylaxis: Novel Pharmacologic and Graft Manipulation StrategiesElizabeth O Hexner, Zachariah DeFilipp
Expert Opinion on Biological Therapy|December 2, 2005
RNA interference for treating haematological malignanciesElizabeth O Hexner, Alan M Gewirtz
Hematology. American Society of Hematology. Education Program|December 10, 2021
Running interferon interference in treating PV/ET: meeting unmet needsElizabeth A Traxler, Elizabeth O Hexner
Case Reports in Hematology|October 16, 2019
Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic LeukemiaRonak H Mistry, Elizabeth O Hexner, James K Mangan
Therapeutic Advances in Hematology|April 5, 2013
Myelofibrosis 2012: it's complicatedHarper G Hubbeling, Dale M Frank, Elizabeth O Hexner
Blood|March 27, 2010
AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2Wei Wang, Sven Schwemmers, Elizabeth O Hexner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2013
Intrinsic resistance to JAK2 inhibition in myelofibrosisAnna Kalota, Grace R Jeschke, Martin Carroll, et al.
Cancer Treatment and Research|September 26, 2009
Cellular adoptive immunotherapy after autologous and allogeneic hematopoietic stem cell transplantationDavid L Porter, Elizabeth O Hexner, Sarah Cooley, et al.
Pageof 11